Since launched in March 2018, under the guidance of the Editor-in-Chief Dr. Godefridus J. Peters, Cancer Drug Resistance (CDR) has always been adhering to the principle of high-quality publication, exploring innovative academic topics and making every effort to publish valuable academic findings. Thus, we have gained trust and support from more and more famous researchers in this field, who are willing to join and contribute to CDR. Though as of 31st December 2020, CDR has not been indexed in important databases such as PubMed, Scopus and Emerging Sources Citation Index (ESCI), in 2020, the total citations of papers published in 2018 and 2019 were 224 times, and the total number of reviews and original articles published were 91. The estimated impact factor is 2.461. Click the link for details of the CDR citation: https://oaepublishstorage.blob.core.windows.net/cdruploadedfiles/Citations_of_CDR_as_of_Dec_31_2020.xls
In 2021, we will complete the database (PubMed, Scopus and ESCI) application work. We believe that based on the strict quality control in the early stage and the support of experts in the field, CDR will make a breakthrough in database application. We also believe that after CDR is indexed in the database, as the exposure increases, it can achieve the first targeted impact factor to 5. At the beginning of the new year in 2021, the Editorial Office would like to express our sincere gratitude again to all Editorial Board members, guest editors, authors, readers and reviewers. We believe that in the near future, CDR will become a leading journal in the field.